Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge advises Main Capital and Björn Lundén in connection with the acquisition of Aprello

Vinge has advised Björn Lundén, a provider of accounting and financial administration software, in connection with the acquisition of Aprello AB (“Aprello”). The strategic acquisition complements Björn Lundén’s growth strategy in the European financial administration software market.
January 30, 2025

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.
January 24, 2025

Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in the divestment of shares in Marshall Group

Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in connection with the divestment of shares in Marshall Group AB (publ) (”Marshall Group”) to HongShan Group, formerly known as Sequoia China. The Marshall Family will continue as owner in the Marshall Group.
January 24, 2025